Alliance Pharma Co., Ltd. Pharmaceutical Import Profile — Thailand (DGFT 2022–2026)

Name: Alliance Pharma Co., Ltd. Pharmaceutical Import Records from India — 2 Products, $250.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Alliance Pharma Co., Ltd. — Pharmaceutical Importer Profile (2026) | 2 Products, $250.0K Trade | TransData Nexus

Alliance Pharma Co., Ltd.

Pharmaceutical Importer · Thailand · Advanced Oncology Focus · $250.0K Total Trade · DGFT Verified

Alliance Pharma Co., Ltd. is a pharmaceutical importer based in Thailand with a total trade value of $250.0K across 2 products in 1 therapeutic categories. Based on 5 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Alliance Pharma Co., Ltd. sources from 2 verified Indian suppliers, with Emcure Pharmaceuticals Limited accounting for 91.1% of imports.

Alliance Pharma Co., Ltd. — Import Portfolio & Supplier Network

Alliance Pharma Co., Ltd. import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Alliance Pharma Co., Ltd.?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Emcure Pharmaceuticals Limited	$1.3M	54	91.1%
Intas Pharmaceuticals Limited	$131.0K	3	8.9%

Alliance Pharma Co., Ltd. sources from 2 verified Indian suppliers across .

What Formulations Does Alliance Pharma Co., Ltd. Import?

Formulation	Value	Ships
Pharma: bicnu 100MG injection	$200.0K	4
Pharma : encifer 100 MG injeciton amp	$100.0K	2
Pharmaceutical products:encifer 100 MG INJ 5x5 ML amp (iron sucrose injection USP 100MG/5ML)	$100.0K	2
Pharmaceuticals products ( finished product) : molena 200 MG capsule 40's ( molnupiravir capsules 200 MG ) ( Pack	$100.0K	2
Pharmaceuticals products( finished product): clopidogrel 75 MG tablet 10x10 ( clopidogrel tablets 75MG )	$68.0K	3
Clopidogrel 75MG tablet(Each TAB.cont:clopidogrel bisulfate USP eq.to clopidogrel 75MG)-10x10t(1pac=1no	$59.5K	3
Pharma : molena capsules 200 MG	$50.0K	1
Pharmaceutical products - encifer	$50.0K	1
Pharmaceutical products : molena 200 MG	$50.0K	1
Pharma: megval 50MG injection	$50.0K	1
Pharmaceutical products:megval 50 MG inj1 vial(melphalan hydrochloride for injection 50MG/vial)	$50.0K	1
Pharmaceuticals products ( finished product) : encifer 100 MG INJ 5x5 ML amp ( iron sucrose injection USP 100MG/5ML )	$50.0K	1
Ph.dru.& med.: zolotem 250MG capsules (Each hard gelatin capsules contains: temozolomide 250MG) [1x5c per	$50.0K	1
Ph.dru.& med.: zolotem 100MG capsules (Each hard gelatin capsules contains: temozolomide 100MG) [1x5c per	$50.0K	1
Pharmaceutical products (finished product)-encifer 100 MG INJ 5x5 ML amp(iron sucrose injection USP 100MG/5ML)	$50.0K	1

Alliance Pharma Co., Ltd. imports 41 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Temozolomide	Advanced Oncology	$150.0K	3	0.6%	17
2	Melphalan	Advanced Oncology	$100.0K	2	0.8%	13

Alliance Pharma Co., Ltd. imports 2 pharmaceutical products across 1 categories into Thailand totaling $250.0K.

Alliance Pharma Co., Ltd. — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Alliance Pharma Co., Ltd. is a privately held pharmaceutical company based in Bangkok, Thailand. Established in 2006 as an extension of Bioscience Co., Ltd., the company has positioned itself as a leading importer and distributor of pharmaceutical and medical device products in Thailand. Its product portfolio includes anticancer medications, psychiatric drugs, iron supplements, and medical devices such as stents and balloon dilatation catheters. In 2024, Alliance Pharma reported total sales revenues of approximately 540 million Baht, reflecting its strong growth trajectory. (alliancepharma.co.th)

In 2024, Alliance Pharma entered into a joint venture with Kalbe Group of Indonesia to further expand its business in Thailand. Kalbe Group is a prominent healthcare company listed on the Indonesia Stock Exchange, offering integrated healthcare solutions across pharmaceutical, consumer health, nutrition, and distribution/logistics sectors. This strategic partnership aims to enhance Alliance Pharma's market presence and operational capabilities within the Thai pharmaceutical industry. (alliancepharma.co.th)

2Distribution Network

Alliance Pharma Co., Ltd. operates a comprehensive distribution network across Thailand, ensuring nationwide coverage. The company's headquarters are located at 128 (1st Floor), Sutthisan Winitchai Road, Samsen Nok, Huai Khwang, Bangkok, Thailand, 10310. While specific warehouse locations are not publicly disclosed, Alliance Pharma emphasizes prompt delivery services, with a commitment to on-time delivery within two days in Bangkok and the metropolitan area. This logistical efficiency underscores the company's dedication to meeting customer needs and maintaining a robust supply chain. (alliancepharma.co.th)

3Industry Role

Alliance Pharma Co., Ltd. serves as a primary wholesaler and distributor within Thailand's pharmaceutical supply chain. By importing and commercializing a diverse range of pharmaceutical and medical device products, the company plays a pivotal role in ensuring the availability of essential medications and medical devices to various healthcare providers across the nation. Its strategic partnerships, such as the joint venture with Kalbe Group, further solidify its position in the market, enabling the company to expand its product offerings and enhance distribution capabilities. (alliancepharma.co.th)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Alliance Pharma Co., Ltd.

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Alliance Pharma Co., Ltd. demonstrates a high degree of sourcing concentration, importing finished pharmaceutical formulations exclusively from two Indian suppliers: Emcure Pharmaceuticals Limited and Intas Pharmaceuticals Limited. Emcure Pharmaceuticals Limited accounts for 91.1% of the total shipments, while Intas Pharmaceuticals Limited comprises 8.9%. This sourcing strategy indicates a strong reliance on these suppliers, which could pose risks related to supply chain disruptions or changes in supplier dynamics. However, the consistent volume of shipments suggests a stable and well-established relationship between Alliance Pharma and its Indian suppliers, potentially mitigating some of these risks.

2Supply Chain Resilience

The resilience of Alliance Pharma Co., Ltd.'s supply chain is closely tied to its concentrated sourcing strategy from two Indian suppliers. While this focus may streamline operations and foster strong supplier relationships, it also exposes the company to potential risks such as supply disruptions or geopolitical issues affecting India. The company's emphasis on prompt delivery services within Bangkok and the metropolitan area indicates a commitment to maintaining supply chain efficiency. However, the lack of publicly available information regarding backup suppliers or alternative sourcing strategies suggests that Alliance Pharma may need to diversify its supplier base to enhance supply chain resilience. (alliancepharma.co.th)

Importing Pharmaceuticals into Thailand — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Thailand

1Regulatory Authority & Framework

In Thailand, the Food and Drug Administration (FDA) is the primary regulatory authority overseeing the pharmaceutical industry. The FDA is responsible for ensuring the safety, efficacy, and quality of pharmaceutical products imported into the country. Key legislation governing pharmaceutical imports includes the Drug Act B.E. 2510 (1967) and its subsequent amendments, which outline the requirements for drug registration, importation, and distribution. The marketing authorization pathway for Indian generics involves obtaining approval from the Thai FDA, which includes submitting comprehensive documentation on product quality, safety, and efficacy, as well as compliance with Good Manufacturing Practice (GMP) standards.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in Thailand mandate that all imported drugs must be registered with the Thai FDA before they can be marketed. This process involves submitting detailed product dossiers, including evidence of GMP compliance from the manufacturing facility. The Thai FDA recognizes GMP certificates from reputable international standards, such as EU GMP, WHO GMP, and PIC/S, facilitating the approval process for foreign manufacturers. Additionally, companies like Alliance Pharma Co., Ltd. must obtain wholesale distribution authorization from the Thai FDA, ensuring that they adhere to regulatory standards in the storage, handling, and distribution of pharmaceutical products.

Alliance Pharma Co., Ltd. — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Alliance Pharma Co., Ltd.'s focus on importing and distributing anticancer products, psychiatric drugs, iron supplements, and medical devices aligns with the growing healthcare needs in Thailand. The increasing prevalence of cancer and mental health conditions in the country drives demand for effective treatments, positioning Alliance Pharma to meet these needs. The inclusion of iron supplements addresses nutritional deficiencies, while medical devices like stents and balloon dilatation catheters cater to the expanding cardiovascular care sector. This strategic product mix enables Alliance Pharma to serve a broad patient demographic and capitalize on emerging healthcare trends.

2Sourcing Profile

Alliance Pharma Co., Ltd. primarily sources generic pharmaceutical products from India, focusing on finished formulations such as tablets, capsules, syrups, and injections. This sourcing strategy leverages India's robust pharmaceutical manufacturing capabilities and cost advantages. The company's emphasis on high-quality products from manufacturers meeting international standards ensures compliance with Thai regulatory requirements and meets the expectations of healthcare providers and patients. By importing finished formulations, Alliance Pharma can expedite market entry and distribution, enhancing its competitiveness in the Thai pharmaceutical market.

Market Positioning

Seller's Guide — How to Become a Supplier to Alliance Pharma Co., Ltd.

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Alliance Pharma Co., Ltd., given the company's concentrated sourcing strategy from two primary suppliers. Indian exporters can explore this opportunity by offering competitive pricing, reliable delivery schedules, and high-quality products that meet Thai regulatory standards. Additionally, diversifying the product range to include innovative formulations or addressing unmet medical needs could further enhance the attractiveness of potential partnerships. Establishing a strong relationship with Alliance Pharma could lead to long-term collaboration and market penetration in Thailand.

2Requirements & Qualifications

Indian exporters seeking to supply Alliance Pharma Co., Ltd. and the Thai market must ensure compliance with the Thai FDA's import licensing requirements, including obtaining GMP certification recognized by the Thai FDA. Products must meet Thai labeling requirements, including information in the Thai language and adherence to serialization mandates. Additionally, exporters should be prepared to provide comprehensive product dossiers for registration and be aware of the regulatory changes affecting pharmaceutical imports into Thailand between 2024 and 2026. Maintaining high-quality standards and staying informed about regulatory developments will be crucial for successful market entry.

Frequently Asked Questions — Alliance Pharma Co., Ltd.

What products does Alliance Pharma Co., Ltd. import from India?

Alliance Pharma Co., Ltd. imports 2 pharmaceutical products across 1 categories. Top imports: Temozolomide ($150.0K), Melphalan ($100.0K).

Who supplies pharmaceuticals to Alliance Pharma Co., Ltd. from India?

Alliance Pharma Co., Ltd. sources from 2 verified Indian suppliers. The primary supplier is Emcure Pharmaceuticals Limited (91.1% of imports, $1.3M).

What is Alliance Pharma Co., Ltd.'s total pharmaceutical import value?

Alliance Pharma Co., Ltd.'s total pharmaceutical import value from India is $250.0K, based on 5 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Alliance Pharma Co., Ltd. focus on?

Alliance Pharma Co., Ltd. imports across 1 categories. The largest: Advanced Oncology (100.0%).

Get Full Alliance Pharma Co., Ltd. Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.